INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,458,520 | -72.4% | 28,000 | -72.0% | 0.76% | -71.7% |
| Q4 2022 | $5,292,000 | +13.7% | 100,000 | 0.0% | 2.69% | +57.6% |
| Q3 2022 | $4,653,000 | +8.7% | 100,000 | +33.3% | 1.71% | -0.4% |
| Q2 2022 | $4,281,000 | +210.9% | 75,000 | +233.3% | 1.71% | +271.6% |
| Q1 2022 | $1,377,000 | -54.1% | 22,500 | -74.5% | 0.46% | -44.6% |
| Q1 2021 | $2,997,000 | -38.5% | 88,326 | -42.4% | 0.83% | -54.3% |
| Q4 2020 | $4,876,000 | – | 153,348 | – | 1.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |